Daily non-political popular news in brief.

Drug reduces daily 'off' time for Parkinson patients

Parkinson disease patients taking the drug, ropinirole 24-hour prolonged release significantly reduced their daily "off" time in which Parkinson's symptoms like tremor, slowness, stiffness and walking difficulty return as drugs wear off, according to a study published in the April 3, 2007, issue of Neurology, the scientific journal of the American Academy of Neurology.

Read more »

Keywords: drug, daily, time, parkinson, patients, patient

« Previous | Next »

Similar news on "Drug reduces daily 'off' time for Parkinson patients":

1. Lifetime trauma may speed progression of HIV, early death
   11-01-2007 · EurekAlert!
   Even though effective drug cocktails have improved the outlook for many patients with HIV, disease progression, including the time from AIDS onset to death, varies widely from patient to patient. Now, a study led by the University of North Carolina at Chapel Hill School of Medicine provides new evidence that psychological factors play a role in disease progression.
   Similar news · Read more »
   
2. Mayo Clinic Cancer Center -- individualizing treatment for multiple myeloma patients
   12-10-2006 · EurekAlert!
   Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells that should increase a patient's chance of responding to the agent.
   Similar news · Read more »
   
3. GI screening: Racing time or wasting time?
   05-22-2007 · EurekAlert!
   Preventative medicine and technology are some of the great benefits in this ever-changing age of health-care technology. Operations that once required major surgery and in-patient stays are being replaced with minimally invasive procedures with quick recovery times. Among these preventative technologies include CT scans, colonoscopies and X-rays. But with all of these available options in detecting abnormalities in patients, how does one choose which test to perform and whether it is worth the time to test on fast-acting ailments? Research presented today at Digestive Disease Week 2007 provides guidance as to which tests are best for which patients. DDW is the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
   Similar news · Read more »
   
4. New drug shows promise for treating epileptic seizures
   04-05-2007 · EurekAlert!
   A new study appearing in the latest issue of Epilepsia shows that a new drug called Eslicarbazepine (ESL) shows promise as a treatment for epilepsy patients whose symptoms remain uncontrolled with existing medications. A once-daily dose was shown to be most effective, offering patients added convenience as current treatments can involve several doses per day.
   Similar news · Read more »
   
5. Study produces conflicting findings on the use of anti-anemia drug in cancer patients
   04-16-2007 · EurekAlert!
   Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.
   Similar news · Read more »
   
6. Researchers discover possible markers for mental illness
   12-03-2007 · EurekAlert!
   Researchers have discovered natural genetic differences that might help predict the most effective antipsychotic drugs for particular patients with mental disorders such as schizophrenia, Parkinson's and drug addiction. They found the differences in the gene for a molecule called the dopamine D2 receptor, a protein present on brain cells that are sensitive to the neurotransmitter dopamine.
   Similar news · Read more »
   
7. Catalyst Pharmaceutical Partners Begins Enrollment for its U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Addiction
   01-25-2008 · Brookhaven National Laboratory
   Catalyst Pharmaceutical Partners, Inc. announced today that it has initiated enrollment of patients for its 180-patient, U.S. Phase II clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vigabatrin.
   Similar news · Read more »
   
8. UCI launches effort to develop patient-specific stem cell lines
   05-14-2007 · EurekAlert!
   UC Irvine neurobiologist Hans Keirstead and his research team today launched a project to develop stem cell lines that genetically match human patients. These lines would allow scientists to better study conditions ranging from diabetes to Parkinson's disease, and they would provide the basis for potential patient-specific stem cell treatments.
   Similar news · Read more »
   
9. Mouse Tests Predict Drug Response In Relapsing Pancreatic Cancer Patients
   10-12-2006 · ScienceDaily
   By slicing up bits of patient tumors and grafting them into mice, Johns Hopkins Kimmel Cancer Center specialists have figured out how to accurately 'test drive' chemotherapy drugs to learn in advance which drug treatments offer each individual pancreatic cancer patient the best therapeutic journey.
   Similar news · Read more »
   
10. Gene patenting -- steep cost for health care and patients
    05-07-2007 · EurekAlert!
    The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
    Similar news · Read more »